Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Pharmacokinetic Interaction Between Atorvastatin and Nifedipine

아톨바스타틴과 니페디핀의 약물동태학적 상호작용

  • Moon, Hong-Seop (Department of pharmacy, Chosun University Hospital, College of Pharmacy, Chosun University) ;
  • Choi, Jun-Shik (Department of pharmacy, Chosun University Hospital, College of Pharmacy, Chosun University)
  • 문홍섭 (조선대학병원 약제부, 조선대학교 약학대학) ;
  • 최준식 (조선대학병원 약제부, 조선대학교 약학대학)
  • Received : 2010.03.20
  • Accepted : 2010.04.02
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to investigate the effect of atorvastatin on the pharmacokinetics of nifedipine (6 mg/kg) after oral administration of nifedipine with or without atorvastatin (0.5 and 2.0 mg/kg) in rats, and also was to evaluate to the effect of atorvastatin on the CYP3A4 activity. The 50% inhibiting concentration ($IC_{50}$) values of atorvastatin on CYP3A4 activity is 46.1 ${\mu}M$. Atorvastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner. Coadministration of atorvastatin increased significantly (p<0.05, 2.0 mg/kg) the plasma concentration-time curve (AUC) and the peak concentration ($C_{max}$) of nifedipine compared to the control group. The relative bioavailability (RB%) of nifedipine was increased from 1.15- to 1.37-fold. Coadministration of atorvastatin did not significantly change the terminal half-life ($T_{1/2}$) and the time to reach the peak concentration ($T_{max}$) of nifedipine. Based on these results, we can make a conclusion that the significant changes of these pharmacokinetic parameters might be due to atorvastatin, which possesses the potency to inhibit the metabolizing enzyme (CYP3A4) in the liver and intestinal mucosa, and also inhibit the P-glycoprotein (P-gp) efflux pump in the intestinal mucosa. It might be suggested that atorvastatin altered disposition of nifedipine by inhibition of both the first-pass metabolism and P-glycoprotein efflux pump in the small intestine of rats. In conclusion, the presence of atorvastatin significantly enhanced the oral bioavailability of nifedipine, suggesting that concurrent use of atorvastatin with nifedipine should require close monitoring for potential drug interation.

Keywords

References

  1. Walter DG, Gruchy BS, Renwick AG, et al., The first pass metabolism of nifedipine in man. Br J Clin Pharmacol 1984; 18: 951-6. https://doi.org/10.1111/j.1365-2125.1984.tb02569.x
  2. Raemsch KD, Sommer JC. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5: 18-24.
  3. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980; 46: 1047-53. https://doi.org/10.1016/0002-9149(80)90366-5
  4. Sorkin E M, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30: 182-7. https://doi.org/10.2165/00003495-198530030-00002
  5. Guengerich FP, Brian WR, Iwasaki M. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4, J Med Chem 1991; 4: 1838-44.
  6. Iribarne C, Dréano LG, Bardou JF, Ménez G, et al., Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997; 117: 13-9. https://doi.org/10.1016/S0300-483X(96)03549-4
  7. Watkins PB, Wrighton SA, Schuetz EG, et al., Identification of glucocorticoid-inducible cytochromes P- 450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-35. https://doi.org/10.1172/JCI113156
  8. Kolars JC, Schmiedlin-Ren P, Dobbins 3rd WO, et al., Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 1992; 102: 1186-92.
  9. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-90. https://doi.org/10.1146/annurev.bi.62.070193.002125
  10. Gan SL, Moseley MA, Khosla B, et al., CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 1996; 24: 344-50.
  11. Watkins PB. The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv Drug Deliv Rev 1996; 27: 161-7.
  12. Wacher VH, Silverman JA, Zhang Y, et al., Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322-8. https://doi.org/10.1021/js980082d
  13. Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm Res 1999; 16: 225-31. https://doi.org/10.1023/A:1018872207437
  14. Chaudhary PM, Robinson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-90. https://doi.org/10.1016/0092-8674(91)90141-K
  15. Van Asperen J, Van Tellingen O, Sparreboom A, et al., Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker. Br J Cancer 1997; 76: 1181-87. https://doi.org/10.1038/bjc.1997.530
  16. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174-80.
  17. Ford JM. Modulators of multidrug resistance preclinical studies. Hematol Oncol Clin N Am 1995; 9: 337-42.
  18. Fruehauf JP, Manetta A. Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib Gynecol Obstet 1994; 19: 39-45.
  19. Endo T, Kimura O, Sakata M. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK. Toxicol Appl Pharmacol 2002; 185: 166-72. https://doi.org/10.1006/taap.2002.9533
  20. Hokama N, Hobara N, Sakai M, et al., Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J Pharm Pharmacol 2002; 54: 821-26. https://doi.org/10.1211/0022357021778998
  21. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53: 828-47. https://doi.org/10.2165/00003495-199753050-00011
  22. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet 2003; 42: 1141-60. https://doi.org/10.2165/00003088-200342130-00005
  23. Boyd RA, Stern RH, Stewart BH, et al., Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8. https://doi.org/10.1177/00912700022008612
  24. Wu X, Whitheld LR, Stewart, BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17: 209-15. https://doi.org/10.1023/A:1007525616017
  25. Holtzman CW, Wiggins BS, Spinler SA. Role of Pglycoprotein in Statin Drug Interactions. Pharmacotherapy 2006; 26: 1601-07. https://doi.org/10.1592/phco.26.11.1601
  26. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-74. https://doi.org/10.1067/mcp.2000.104609
  27. Choi DH, Chang KS, Hong SP, et al., Effect of Atorvastatin on the Intravenous and Oral Pharmacokinetics of Verapamil in Rat. Biopharm Drug Dispos 2008; 29: 45- 50. https://doi.org/10.1002/bdd.582
  28. Hong SP, Chang KS, Choi DH, et al., Effect od Atorvastatin on the Pharmacokinetics of Diltiazem and Its main metabolite, Desacetyldiltiazem, in rats. Arch Pharm Res 2007; 30; 90-95. https://doi.org/10.1007/BF02977783
  29. Choi BC, Choi JS. Pharmacokinetic interaction between simvastatin and nicardipine. Kor J Clin Pharm 2009; 19: 32-36.
  30. Choi DH, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Durg Metabol 2009; 34: 163- 168. https://doi.org/10.1007/BF03191168
  31. Grundy JS, Kherani R, Foster RT. Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr B Biomed Appl 1994; 654: 146-52. https://doi.org/10.1016/0378-4347(93)E0449-Z
  32. Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 1983; 16: 203-9. https://doi.org/10.1016/0010-468X(83)90082-X
  33. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-90. https://doi.org/10.1146/annurev.bi.62.070193.002125
  34. Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 1999; 16: 225-31. https://doi.org/10.1023/A:1018872207437